Blog
Top Autoinjector Companies in Australia & New Zealand: Company Analysis 2026
Company Analysis | Medical Devices | Australia & New Zealand
By Global Data Route Analytics Research Team · Published 26 September 2026 · 12 min read
The Australia and New Zealand autoinjectors market has changed more in the last two years than in the previous twenty. Anapen left the Australian market, leaving EpiPen as the only adrenaline autoinjector for about a year. A new competitor, Jext, arrived on the PBS in June 2026, a needle-free adrenaline nasal spray followed, and CSL launched the world's first prefilled pen for hereditary angioedema (HAE) prevention with an Australian world-first approval.
In this Australia and New Zealand autoinjectors market company analysis, we profile the key companies behind these changes: their background, product portfolio, recent developments, financial snapshot and contact details. We then map the vendor landscape, competitive environment, M&A activity, strategy and a competitive heat map.
Key findings
- Adrenaline autoinjectors are the core of the market. Australia has one of the highest food allergy rates in the world, with about 10% of Melbourne infants showing challenge-confirmed food allergy in the HealthNuts study.
- Competition is returning. After Anapen's exit in 2024–2025, Biocelect's Jext joined the PBS on 1 June 2026, ending EpiPen's period as the only PBS-listed autoinjector.
- CSL leads on innovation. Its ANDEMBRY (garadacimab) prefilled pen won a world-first TGA approval in January 2025, a PBS listing on 1 April 2026 and a Medsafe approval in New Zealand.
- New Zealand is a narrower market. EpiPen is the only Pharmac-funded adrenaline autoinjector (since February 2023), and Jext has no Medsafe registration yet.
~10%
Melbourne infants with food allergy (HealthNuts)
1 Jun 2026
Jext adrenaline autoinjector PBS listing
1 Apr 2026
CSL ANDEMBRY pen PBS listing
US$15.6 bn
CSL FY25 total operating revenue
Who Are the Key Autoinjector Companies in Australia and New Zealand?
The key autoinjector companies and brands in Australia and New Zealand are:
- CSL Limited: Australian biotech leader; ANDEMBRY prefilled autoinjector pen for HAE
- Biocelect Pty Ltd: Australian sponsor of the Jext adrenaline autoinjector (PBS-listed 2026)
- SciGen Australia Pty Ltd: sponsor of the Nemera-made SciTropin A reusable growth hormone pen
- Allergy Life Australia: patient-support charity and Anapen information channel
- Viatris (EpiPen): long-standing market-leading adrenaline autoinjector in both countries
- Arrotex Pharmaceuticals (Anapen): former Anapen supplier; all doses withdrawn by mid-2025
Table of Contents
- Adrenaline Autoinjector Market Snapshot
- Company Overview at a Glance
- Product Mapping Analysis
- Detailed Company Analysis
- Recent Developments Timeline
- Competitive Landscape Analysis
- Vendor Landscape
- Competitive Environment
- Merger & Acquisition Analysis
- Strategy Framework
- Heat Map Analysis
- Frequently Asked Questions
- Conclusion
Adrenaline Autoinjector Market Snapshot
Adrenaline (epinephrine) autoinjectors for anaphylaxis are the largest and most visible part of the ANZ autoinjectors market. This table shows the status of each device as of September 2026.
| Device | Sponsor / Supplier | Doses | Australia (TGA / PBS) | New Zealand | 2026 Status |
|---|---|---|---|---|---|
| EpiPen / EpiPen Jr | Viatris | 300 mcg / 150 mcg | PBS-listed | Pharmac-funded since Feb 2023 | Available |
| Jext / Jext Jnr | Biocelect (made by ALK-Abelló) | 300 mcg / 150 mcg | TGA 14 Nov 2025; PBS 1 Jun 2026 | Not registered | New 2026 |
| Anapen 500 / 300 / Jr 150 | Arrotex Pharmaceuticals | 500 / 300 / 150 mcg | PBS-listed from Sep 2021 | Not confirmed | Withdrawn |
| neffy (nasal spray) | Needle-free alternative | 2 mg / 1 mg | TGA 8 Dec 2025; PBS 1 Jul 2026 | Not registered | Alternative |
Anapen 300 and Anapen Jr 150 were discontinued in July and September 2024 for lack of demand, and Anapen 500 went out of stock from July 2025 because of a global supply shortage.
Company Overview at a Glance
The four companies profiled in this analysis come from the company links reviewed for this study; figures marked * are third-party or self-reported estimates.
| Company | HQ | Founded | Positioning | Scale indicator |
|---|---|---|---|---|
| CSL Limited | Melbourne, VIC | 1916 | Global biotech; ANDEMBRY prefilled pen | FY25 revenue US$15,558M; ~29,000 staff |
| Biocelect Pty Ltd | Sydney, NSW + Christchurch, NZ | 2014* | Specialty medicines sponsor; Jext autoinjector | Private; ~12–14 staff* |
| SciGen Australia Pty Ltd | NSW (group HQ Singapore) | 1992 (AU) | Growth hormone + Nemera reusable pen | Private; owned by YiFan International |
| Allergy Life Australia | Australia (national, online) | Not disclosed | Allergy patient-support charity; Anapen listing | Registered charity (DGR) |
Product Mapping Analysis
This matrix maps each company across the main autoinjector and self-injection categories in Australia and New Zealand.
| Company | Adrenaline autoinjector | Biologic prefilled pen | Growth hormone pen | Reusable device | PBS-listed device product | NZ presence | Patient education & support |
|---|---|---|---|---|---|---|---|
| CSL Limited | – | ✓ | – | – | ✓ | ✓ | – |
| Biocelect | ✓ | – | – | – | ✓ | ✓ | – |
| SciGen Australia | – | – | ✓ | ✓ | – | – | – |
| Allergy Life Australia | Listing | – | – | – | – | – | ✓ |
✓ Offers / applies Listing Information or listing channel only – Not offered. NZ presence for CSL reflects Medsafe approval of ANDEMBRY; for Biocelect, its Christchurch office.
Need full product benchmarking for every autoinjector brand in Australia and New Zealand?
Get Free Sample →Detailed Company Analysis
Each profile covers the company background, products, recent developments, financials and contact details, with links to the official sources.
Want deeper profiles, market shares and forecasts?
Speak with our analysts about company benchmarking and segment data for the Australia and New Zealand autoinjectors market.
Inquire Before BuyingRecent Developments Timeline
Sep 2021
Anapen is listed on the PBS in Australia.
Feb 2022
TGA approves SciGen's Nemera-made SciTropin A reusable growth hormone pen.
Feb 2023
Pharmac begins fully funding EpiPen in New Zealand.
Jul–Sep 2024
Anapen 300 and Anapen Jr 150 are discontinued in Australia.
Jan 2025
TGA grants CSL's ANDEMBRY a world-first approval.
Jul 2025
Anapen 500 goes out of stock, leaving EpiPen as the only adrenaline autoinjector in Australia.
Nov 2025
TGA registers Biocelect's Jext and Jext Jnr.
Dec 2025
CSL opens a $1 billion-plus vaccine and antivenom facility in Melbourne.
Mar 2026
Medsafe approves ANDEMBRY in New Zealand.
Apr 2026
ANDEMBRY is listed on the PBS.
Jun 2026
Jext is listed on the PBS and launched.
Jul 2026
neffy adrenaline nasal spray is listed on the PBS as a needle-free alternative.
Competitive Landscape Analysis
The ANZ market is small and concentrated, and most devices are imported. Companies compete through regulatory approvals, PBS and Pharmac listings, and supply reliability rather than local manufacturing. The players fall into three groups:
Tier 1: Global innovator with local manufacturing
CSL Limited (with Viatris’ EpiPen as the established adrenaline leader)
Large-scale companies with strong regulatory records and reimbursed products. CSL leads in biologic prefilled pens; EpiPen remains the default adrenaline device in both countries.
Tier 2: Specialist sponsors and distributors
Biocelect, SciGen Australia
Lean companies that in-license proven devices from global makers (ALK-Abelló, Nemera) and win share through PBS listings and focused marketing.
Tier 3: Patient ecosystem
Allergy Life Australia
Charities and patient groups that shape awareness, training and device choice, and feel supply shocks first.
What will decide the winners?
- Reimbursement: PBS listing in Australia and Pharmac funding in New Zealand decide which devices patients actually get.
- Supply reliability: the Anapen withdrawal showed that one supply failure can remove a brand from the market.
- New Zealand entry: Medsafe registration and Pharmac funding are the next frontier for Jext and other challengers.
- Needle-free alternatives: nasal adrenaline (neffy) will push autoinjector makers to improve ease of use and training.
Vendor Landscape
The vendor landscape groups each company by business model, core offering, therapy area, geographic reach and credentials.
| Company | Vendor Type | Core Offering | Therapy Area | Geographic Reach | Credentials |
|---|---|---|---|---|---|
| CSL Limited | Global Innovator | ANDEMBRY prefilled autoinjector pen | Hereditary angioedema; plasma therapies; vaccines | Australia, NZ and 120+ countries | TGA, PBS, Medsafe, FDA, EMA approvals |
| Biocelect | Specialty Sponsor | Jext / Jext Jnr adrenaline autoinjectors | Anaphylaxis; travel medicine; vaccines | Australia, NZ, South Pacific | TGA registered; PBS listed |
| SciGen Australia | Device-Partnered Sponsor | SciTropin A + Nemera reusable pen | Growth hormone deficiency | Australia; Asia-Pacific group | TGA approved pen (2022) |
| Allergy Life Australia | Patient Ecosystem | Anapen listing, support programs | Allergy and anaphylaxis | Australia (national) | Registered DGR charity |
Competitive Environment
Using Porter's Five Forces, the table below shows how intense competition is in the Australia and New Zealand autoinjectors market and why.
| Force | Intensity | Market Evidence | Strategic Implication |
|---|---|---|---|
| Competitive Rivalry | Medium
|
Only two PBS-listed adrenaline autoinjectors (EpiPen and Jext) in 2026; rivalry is rising after years of near-monopoly. | Compete on training, device features and supply reliability. |
| Threat of New Entrants | Low-Medium
|
TGA registration, PBS listing and Pharmac funding are slow and costly for a small population. | Partner with global device makers to shorten the path. |
| Bargaining Power of Buyers | High
|
The PBS and Pharmac act as powerful single buyers that set prices and funding terms. | Build strong cost-effectiveness cases for reimbursement. |
| Bargaining Power of Suppliers | Medium-High
|
Most devices are made overseas (ALK-Abelló, Nemera, Viatris); the Anapen shortage showed supply risk. | Secure multi-source supply and local stock buffers. |
| Threat of Substitutes | Medium
|
neffy nasal adrenaline spray was PBS-listed in July 2026 as a needle-free option. | Differentiate with ease of use, clear dosing and patient trust. |
Merger & Acquisition Analysis
Deal activity in the ANZ autoinjectors space is mostly about licensing, acquisitions by parent groups and large capital investment, rather than frequent local mergers.
| Date | Deal / Parties | Type | Value | Strategic Rationale | Market Impact |
|---|---|---|---|---|---|
| 2022 | CSL acquires Vifor Pharma | Acquisition | Approx. US$11.7 bn | Adds iron and nephrology franchise; creates CSL Vifor. | Strengthens CSL's global specialty portfolio and scale. |
| Aug 2018 | YiFan International Pharmaceutical acquires SciGen Ltd from Bioton | Acquisition | Approx. $28 M | Takes SciGen private and adds its Asia-Pacific biopharma network. | SciGen continues as sponsor of growth hormone pens in Australia. |
| 2025–2026 | Biocelect brings ALK-Abelló's Jext to Australia | In-licensing / Distribution | Undisclosed | Adds a proven European autoinjector to Biocelect's allergy portfolio. | Restores competition to EpiPen on the PBS from June 2026. |
| Dec 2025 | CSL Seqirus opens Melbourne facility | Capital Investment | $1 bn+ | Local vaccine and antivenom manufacturing capacity. | Reinforces Australia's sovereign biologics manufacturing. |
| 2024–2025 | Arrotex withdraws Anapen | Market Exit | n/a | Low demand for 300/150 doses; global supply failure for 500 mcg. | Leaves a gap now being filled by Jext and neffy. |
Outlook: expect more in-licensing deals that bring proven overseas autoinjectors and needle-free devices to ANZ, especially for New Zealand, where only one adrenaline autoinjector is currently funded.
Strategy Framework
The framework below shows each company's main strategy, growth levers, key strength and the main risk to watch.
| Company | Core Strategy | Growth Levers | Key Strength | Watch-out |
|---|---|---|---|---|
| CSL Limited | Innovation-led Global Scale | World-first approvals; PBS and Medsafe access for ANDEMBRY; local manufacturing investment | Scale, R&D, manufacturing and regulatory strength | FY26 reset and impairments; HAE is a niche indication |
| Biocelect | In-licensing & Reimbursement | PBS listing of Jext; potential NZ registration; allergy portfolio growth | Agile sponsor with a PBS-listed autoinjector | Small team competing against EpiPen's brand strength |
| SciGen Australia | Device Partnership Niche | Nemera pen platform; growth hormone patient base; group portfolio | Proven device partner and ARTG-listed products | Limited public data and narrow indication |
| Allergy Life Australia | Community & Advocacy | Support groups, apps, cost-assistance programs | Direct reach into the allergy community | Depends on donations; not a supplier |
Heat Map Analysis
The heat map scores each company from 1 (low) to 5 (high) on seven competitive factors. These are analyst scores based on the public information in this blog; darker cells mean a stronger position.
| Company | Autoinjector Portfolio | PBS / Pharmac Access | Regulatory Track Record | Local ANZ Presence | Financial Strength | Innovation | Patient Engagement | Total /35 |
|---|---|---|---|---|---|---|---|---|
| CSL Limited | 3 | 4 | 5 | 5 | 5 | 5 | 3 | 30 |
| Biocelect | 4 | 4 | 4 | 4 | 2 | 3 | 3 | 24 |
| SciGen Australia | 3 | 3 | 4 | 3 | 2 | 3 | 2 | 20 |
| Allergy Life Australia | 1 | 1 | 1 | 4 | 1 | 2 | 5 | 15 |
Reading the heat map: CSL leads on regulatory strength, financial scale and innovation. Biocelect has the strongest adrenaline autoinjector position among the specialist sponsors thanks to Jext's PBS listing. SciGen holds a focused niche in growth hormone pens, while Allergy Life Australia scores highest on patient engagement.
Want the complete heat map scoring, market size and forecasts?
Download Sample Report →Frequently Asked Questions
What is the Australia and New Zealand autoinjectors market?
It covers devices that let patients self-inject a pre-measured dose of medicine, including adrenaline autoinjectors for anaphylaxis, prefilled pens for biologics such as CSL's ANDEMBRY, and pen injectors for hormones such as growth hormone.
Which adrenaline autoinjectors are available in Australia in 2026?
EpiPen (Viatris) and Jext (Biocelect) are the PBS-listed adrenaline autoinjectors in 2026. Anapen was withdrawn between 2024 and 2025, and neffy, a needle-free nasal adrenaline spray, was PBS-listed in July 2026.
Which adrenaline autoinjector is funded in New Zealand?
EpiPen is the Pharmac-funded adrenaline autoinjector in New Zealand, fully funded since 1 February 2023. Jext and neffy do not yet have Medsafe registration or Pharmac funding.
When was Jext listed on the PBS?
Biocelect's Jext adrenaline autoinjector was registered with the TGA on 14 November 2025 and listed on the PBS on 1 June 2026, in 300 mcg and 150 mcg (Jext Jnr) doses.
What is CSL's ANDEMBRY autoinjector?
ANDEMBRY (garadacimab) is a once-monthly prefilled autoinjector pen that prevents hereditary angioedema attacks. The TGA approved it in January 2025 as a world first, and it was listed on the PBS on 1 April 2026.
Why was Anapen withdrawn from Australia?
Anapen 300 and Anapen Jr 150 were discontinued in 2024 because of low demand, and Anapen 500 went out of stock from July 2025 because of an unresolvable global supply shortage.
How can I get the full Australia and New Zealand autoinjectors market report?
You can download a free sample, ask our analysts a question, or request a discount on the Australia and New Zealand Autoinjectors Market report.
Conclusion
The Australia and New Zealand autoinjectors market is small but important, driven by one of the world's highest allergy rates and a growing shift to self-injected biologics. After the Anapen withdrawal, Biocelect's Jext has brought competition back to adrenaline autoinjectors, while CSL's ANDEMBRY shows the next wave of long-term, pen-based therapies. Specialist sponsors such as SciGen and patient groups such as Allergy Life Australia complete the ecosystem. For manufacturers, investors and healthcare buyers, reimbursement decisions, supply reliability and New Zealand market access will define the next few years.
Research Methodology & Sources
This analysis is based on each company's official website, annual reports, TGA, PBS, Medsafe and Pharmac information, and announcements from ASCIA (the Australasian Society of Clinical Immunology and Allergy), reviewed in September 2026. Third-party estimates are marked as such.
- ASCIA: Jext and neffy TGA registration
- ASCIA: Anapen 500 supply update
- ASCIA: Anapen 300 and Jr discontinuation
- Pharmac: EpiPen funding in New Zealand
- newsGP: neffy added to the PBS
- CSL: $1bn Melbourne facility opens
- Medsafe: ANDEMBRY data sheet
- MCRI: HealthNuts food allergy study
- ALK-Abelló: Jext introduction
- MarketScreener: YiFan acquisition of SciGen
Get the Full Australia & New Zealand Autoinjectors Market Report
Market size, forecasts, segmentation and in-depth company profiles in one report. See the free sample first, with no obligation.
Download SampleMake an InquiryRequest Discount